Society of Dermatology Physician Assistants

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.

Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.

Lisa Swanson, MD, explains how building resiliency is crucial for coping with burnout.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

Lisa Swanson, MD, discusses the pathogenesis of atopic dermatitis and why she does not recommend elimination diets for her pediatric patients.

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

The new approval expands the treatment area by 4 times the previously approved area—from 25 cm2 to 100 cm2.

Lisa Swanson, MD, discusses the recent advancements in pediatric dermatology and emphasizes the importance of correctly diagnosing conditions to improve patient outcomes.

An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.

A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.

An interview with Dr. Rosen regarding his SDPA 2022 presentation on dermatologic conditions with white spots that are often misdiagnosed as vitiligo.

A discussion with Dr. Rosen on one of his SPDA 2022 presentations, highlighting his reason for choosing the topic and exploring vitiligo misdiagnosis.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

A discussion with Dr. Orozco on her SDPA 2022 presentation, discussing useful resources for physicians and PAs looking to get involved in the PAs Go Beyond campaign.

In her SDPA 2022 presentation interview, Dr. Katta explores gaps in knowledge regarding the connection between skin disease and dietary health, as well as ways to address these concerns.

Dr. Katta’s interview regarding her SDPA 2022 presentation, during which she discusses the topic of obesity, dietary health, and their relationship with skin conditions like psoriasis.

Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.

Long-term, real-world data show the IL-23 inhibitor benefits patient-reported measures of psychological wellbeing.

New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.

An interview with Dr. Katta on her SDPA 2022 presentation, in which she covers the topic of obesity and its relationship to skin conditions such as plaque psoriasis.

In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

During her SDPA 2022 presentation, Cynthia Trickett explored the topic of psoriasis, including comorbidities and treatment options.

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

An interview on several major highlights from Dr. Orozsco’s presentation about the greater visibility and importance of physician associates at SDPA 2022.